Sahlgrenska University Hospital first Swedish site in the largest ever prospective clinical study for early detection of pancreatic cancer
Designed to validate IMMrayTM PanCan-d, the first blood based test for early detection of pancreatic cancerLUND and Gothenburg, Sweden ― Immunovia AB today announced that Sahlgrenska University Hospital is the first Swedish site to be part of PanFAM-1, a multicenter prospective validation study for the early diagnosis in familiar pancreatic cancer (FPC) high risk individuals. Designed to validate Immunovia ́s blood test, IMMrayTM PanCan-d, the study which started one year ago at Ramon y Cajal Institute for Health Research (IRYCIS) in Madrid, Spain, will analyze thousand individuals for